Articles tagged with Umbilical Cord
A recent study has found that umbilical cord blood transplants can be a successful treatment option for children with inherited metabolic disorders, offering improved outcomes compared to bone marrow transplants. The procedure has shown advantages in terms of availability and reduced risk of complications.
Scientists have found distinct gene expression signatures in the umbilical cords of premature infants who developed bronchopulmonary dysplasia, a fatal lung disorder. These signatures were associated with chromatin remodelling and histone acetylation pathways, providing a potential proxy for predicting disease risk.
A study of over 4000 twin pregnancies found that complex assisted reproduction procedures increase the likelihood of abnormal umbilical cord development. The research suggests that embryo implantation may play a role in this increased risk.
A recent study published in The Lancet found that mismatched cord blood transplants performed as well as matched bone marrow transplants in terms of leukemia-free survival rates. Additionally, patients receiving matched cord blood had a 20% higher survival rate than those with matched bone marrow.
Researchers found that unrelated umbilical cord blood transplants can provide similar five-year survival rates to allele-matched bone marrow transplants for children with acute leukemia. However, matched cord blood transplants showed greater survival rates but required further study to confirm.
Private cord blood banking is praised as a way to increase available cells, with Richard Branson's Virgin Health Bank offering processing and storage options. The bank's dual public-private approach donates one-fifth of samples to those in need at no cost.
The study presents positive interim results of using ALDESORT to isolate cord blood stem cells, showing improved overall survival at 90.9% compared to a historical control group. The infusion of cells enriched with ALDESORT appears to improve the speed and efficacy of cord blood transplantations.
A study published in The Lancet found that delaying umbilical cord clamping for two minutes at birth significantly increases a child's iron status, particularly among those with low birth weights or iron-deficient mothers. This efficient and low-cost method can help prevent iron deficiency before 6 months of age.
A study published in The Lancet found that using chlorhexidine on newborns' umbilical cords significantly reduces the risk of infection and mortality. In contrast, traditional dry cord care practices associated with increased risks of neonatal death were shown to be ineffective.
Researchers debate the ethics of commercial cord blood banking, citing logistical difficulties and low probabilities of use. While some argue for private sector involvement, others raise concerns about exploiting emotional vulnerabilities of parents for financial gain.
The UI Hematopoietic Stem Cell Bank provides cord blood stem cells for advancing gene therapy and treating conditions like Parkinson's disease. Nearly 20 mothers have donated their child's umbilical cord blood, supporting scientific and medical advances.
Researchers at Saint Louis University found that injecting human umbilical cord blood cells into rats after a stroke improved sensorimotor function. The treatment may provide a potential source for restoring neuronal function after a stroke.
A study of nearly 22,000 infants found that only one case of seizures was linked to a low Apgar score and high umbilical cord acid levels. Seizures were common in babies born weighing less than 3.3 pounds, affecting 6% of those cases.
Researchers found that human umbilical cord blood cells improved motor and sensory abilities in rats after stroke, even when administered a week after onset. The study suggests these cells may be used to treat early stroke and other traumatic brain injuries through less invasive IV administration.
Researchers found that stray maternal cells in umbilical cord blood transplants can engraft and cause graft-versus-host disease symptoms. Treatment involves withdrawing anti-GVH medications, allowing the immune system to reject transient maternal cells.
The largest series of unrelated cord blood transplants confirms the feasibility of transplantation for patients without a matching donor. The study demonstrates success in children and mismatched transplants with reduced acute graft versus host disease incidence.